
Taisho Pharmaceutical Holdings Co., Ltd. Certificado de depósito · US87402P1057 (OTC) — cotizaciones en tiempo real, datos de la empresa, dividendos, fundamentales y análisis de cartera con IA en MoneyPeak
Análisis impulsado por IA
Análisis fundamental
Descubre lo que realmente dicen los números — antes que el mercado
Analizar ahora
Sentimiento de noticias
¿Las noticias de hoy son una señal de compra o una alerta?
Analizar ahora
Comprar / Mantener / Vender
¿Comprar, mantener o vender? Obtén el veredicto de la IA ahora.
Analizar ahora
Evaluación de riesgos
Descubre riesgos ocultos antes de que afecten a tu cartera.
Analizar ahora
Valor justo
¿Esta acción está barata, correctamente valorada o sobrevalorada?
Analizar ahora
Últimos análisis de IA sobre Taisho Pharmaceutical Holdings Co., Ltd.
Sin cotización
Perfil de la empresa para Taisho Pharmaceutical Holdings Co., Ltd. Certificado de depósito
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. This segment also engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.
Datos de la empresa
Nombre Taisho Pharmaceutical Holdings Co., Ltd.
Empresa Taisho Pharmaceutical Holdings Co., Ltd.
Sitio web
https://www.taisho-holdings.co.jp
Mercado principal
UTC
ISIN US87402P1057
Tipo de valor Certificado de depósito
Sector Healthcare
Industria Drug Manufacturers - Specialty & Generic
CEO Akira Uehara
Capitalización de mercado 18 Mrd.
País Japón
Moneda USD
Empleados 8,8 T
Dirección 3-24-1 Takada, 170-8655 Tokyo
Fecha de OPV 2021-01-08
Dividendos de 'Taisho Pharmaceutical Holdings Co., Ltd.'
| Fecha ex-dividendo | Dividendo por acción |
|---|---|
| 28.09.2023 | 0,09 USD |
| 30.03.2023 | 0,09 USD |
| 29.09.2022 | 0,09 USD |
| 29.03.2022 | 0,09 USD |
| 28.09.2021 | 0,11 USD |
| 29.03.2021 | 0,11 USD |
| 12.04.2018 | 0,14 USD |
Símbolos de cotización
| Nombre | Símbolo |
|---|---|
| Over The Counter | TAIPY |
Otras acciones
Los inversores que tienen Taisho Pharmaceutical Holdings Co., Ltd. también tienen las siguientes acciones en su cartera:
